Abstract
Parkinson’s disease (PD) is amongst the most frequent neurodegenerative disorders, the main pathologic hallmark of which is the degeneration of the substantia nigra pars compacta. Damage to multiple cellular components, such as mitochondrial dysfunction, oxidative stress, neuroinflammation, and proteasomal dysfunction, contribute to the progression of the neurodegenerative process.
Peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists, mainly thiazolidinediones, pioglitazone and rosiglitazone, have been successfully tested for their neuroprotective potential in PD experimental models, although the cellular target and underlying mechanism are currently a matter of debate. While the anti-inflammatory activity and attenuation of microgliosis have been proposed as a main mechanism of neuroprotection, other cellular targets might be involved, such as mitochondrial proteins controlling cellular bioenergetic and oxidative stress. Here, the current evidence of neuroprotection by PPAR-γ agonists in in vitro and in vivo experimental PD models is reported. Moreover, cellular pathways which have been investigated as potential targets of neuroprotection are reviewed. Taken together, the available data suggest that simultaneous targeting of multiple dysfunctional pathways may underlie the potent neuroprotective activity displayed by PPAR-γ agonists.
Keywords: Cytokines, dopamine, microglia, neuroprotection, neuroinflammation, oxidative stress, Parkinson, PPAR.
Current Drug Targets
Title:PPAR-γ: Therapeutic Prospects in Parkinson's Disease
Volume: 14 Issue: 7
Author(s): Anna R. Carta
Affiliation:
Keywords: Cytokines, dopamine, microglia, neuroprotection, neuroinflammation, oxidative stress, Parkinson, PPAR.
Abstract: Parkinson’s disease (PD) is amongst the most frequent neurodegenerative disorders, the main pathologic hallmark of which is the degeneration of the substantia nigra pars compacta. Damage to multiple cellular components, such as mitochondrial dysfunction, oxidative stress, neuroinflammation, and proteasomal dysfunction, contribute to the progression of the neurodegenerative process.
Peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists, mainly thiazolidinediones, pioglitazone and rosiglitazone, have been successfully tested for their neuroprotective potential in PD experimental models, although the cellular target and underlying mechanism are currently a matter of debate. While the anti-inflammatory activity and attenuation of microgliosis have been proposed as a main mechanism of neuroprotection, other cellular targets might be involved, such as mitochondrial proteins controlling cellular bioenergetic and oxidative stress. Here, the current evidence of neuroprotection by PPAR-γ agonists in in vitro and in vivo experimental PD models is reported. Moreover, cellular pathways which have been investigated as potential targets of neuroprotection are reviewed. Taken together, the available data suggest that simultaneous targeting of multiple dysfunctional pathways may underlie the potent neuroprotective activity displayed by PPAR-γ agonists.
Export Options
About this article
Cite this article as:
Carta Anna R., PPAR-γ: Therapeutic Prospects in Parkinson's Disease, Current Drug Targets 2013; 14 (7) . https://dx.doi.org/10.2174/1389450111314070004
DOI https://dx.doi.org/10.2174/1389450111314070004 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology Renin-Angiotensin-Aldosterone System Antagonists and the Prevention of Type 2 Diabetes Mellitus
Current Pharmaceutical Design Modulation of Mitochondrial Permeability Transition in Ischemia-Reperfusion Injury of the Heart. Advantages and Limitations
Current Medicinal Chemistry Stable Gastric Pentadecapeptide BPC 157-NO-system Relation
Current Pharmaceutical Design Myxedema Heart Disease: A Rare Disease Entity: Case Report and Brief Review of the Literature
Current Hypertension Reviews Heart Disease Induced by AAS Abuse, Using Experimental Mice/Rats Models and the Role of Exercise-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Relaxin in Vascular Physiology and Pathophysiology: Possible Implications in Ischemic Brain Disease
Current Neurovascular Research Advancements in Treatment Options of Women Infertility
Current Women`s Health Reviews Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Brain-Skin Connection: Stress, Inflammation and Skin Aging
Inflammation & Allergy - Drug Targets (Discontinued) Preparation, Pharmacokinetic and Application of Gold Nanoclusters (AuNCs) in Tumor Treatment
Current Medicinal Chemistry A Novel Design of Combining the Angiotensin Converting Enzyme (ACE) Inhibitor Captopril with the Angiotensin Receptor Blocker (ARB) Losartan Using Homo Coupling via PEG Diacid Linker
Recent Patents on Cardiovascular Drug Discovery Subject index to volume 3
Current Molecular Medicine Role of Ischemic Blood-Brain Barrier on Amyloid Plaques Development in Alzheimers Disease Brain
Current Neurovascular Research Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine The Role of the Methoxyphenol Apocynin, a Vascular NADPH Oxidase Inhibitor, as a Chemopreventative Agent in the Potential Treatment of Cardiovascular Diseases
Current Vascular Pharmacology A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets